Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rimonabant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 9/20 | 1.00 |
| ▸ | CNR2 | P34972 | 5/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | CCKAR | P32238 | 1/20 | 1.00 |
| ▸ | CCKBR | P32239 | 1/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rimonabant SCHEMBL29373177 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Rimonabant SCHEMBL1186698 | 0.99 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Rimonabant SCHEMBL29835931 | 0.99 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL12053639 | 0.99 | CNR1 (0.98) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Rimonabant SCHEMBL746112 | 0.98 | CNR1 (0.96) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Rimonabant SCHEMBL8742390 | 0.97 | CNR1 (0.94) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| Rimonabant SCHEMBL8742211 | 0.96 | CNR1 (0.93) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL14397516 | 0.96 | CNR1 (0.92) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL29386088 | 0.95 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 | |
| SCHEMBL1040316 | 0.95 | CNR1 (1.00) | CNR1CNR2CYP2C9GPR55ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17028 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115192-A1 | PHARMACEUTICAL COMPOSITIONS | SHENZHEN PHARMACIN CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | UNIV JOHNS HOPKINS (US) | 2026-04-16 | — | — | US | claimed |
| US-20260097051-A1 | CANNABICHROMENE AS A THERAPEUTIC MODALITY FOR COVID-19 | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2026-04-09 | — | — | US | claimed |
| US-20260056214-A1 | DIAGNOSING AND TREATING END-STAGE RENAL DISEASE (ESRD) IN OBESE SUBJECTS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2026-02-26 | — | — | US | claimed |
| US-12544366-B2 | Combination of endocannabinoid and mTOR inhibitors in the treatment of neuroendocrine neoplasms | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2026-02-10 | — | — | US | claimed |
| EP-4358962-B1 | TREATMENT FOR AUTOIMMUNE DISEASES COMPRISING NALTREXONE OR A METABOLITE OR ANALOG THEREOF, A CANNABINOID AND A 5-HT RECEPTOR AGONIST | LDN PHARMA LTD (GB) | 2026-02-04 | — | — | EP | claimed |
| US-12510524-B2 | Compositions containing cannabinoid analog conjugates and methods of use | VYRIPHARM ENTERPRISES, LLC (US) | 2025-12-30 | — | — | US | claimed |
| US-20250367134-A1 | PERIPHERALIZATION OF CENTRALLY-ACTING CANNABINOID-1 RECEPTOR ANTAGONISTS BY NANOPARTICLES FOR THE TREATMENT METABOLIC RELATED CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-12-04 | — | — | US | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| US-20250352559-A1 | Transdermal Delivery Composition for Delivery of at least one Glucose Controlling Agent, and Method of Delivering at least one Glucose Controlling Agent | SKINVISIBLE PHARMACEUTICALS INC (US) | 2025-11-20 | — | — | US | claimed |
| EP-1221952-A1 | USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONIST FOR PREPARING MEDICINES | Sanofi-Aventis (FR) | 2002-07-17 | — | — | EP | claimed |
| US-6344474-B1 | Use of central cannabinoid receptor antagonists for regulating appetence | SANOFI-SYNTHELABO (FR) | 2002-02-05 | — | — | US | claimed |
| WO-2001085092-A2 | ANTIDIARRHEAL CANNABINOID CB-1 RECEPTOR ANTAGONIST | SANOFI-SYNTHELABO (FR) | 2001-11-15 | — | — | WO | claimed |
| WO-2001058450-A2 | USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONIST FOR PREPARING MEDICINES DESIGNED TO FACILITATE SMOKING CESSATION | SANOFI-SYNTHELABO (FR) | 2001-08-16 | — | — | WO | claimed |
| EP-0969832-B1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF A N-PIPERIDINO- 3-PYRAZOLECARBOXAMIDE DERIVATIVE, ITS SALTS AND THEIR SOLVATES | SANOFI SYNTHELABO (FR) | 2001-07-04 | — | — | EP | claimed |
| WO-2001024798-A1 | USE OF CENTRAL CANNABINOID RECEPTOR ANTAGONIST FOR PREPARING MEDICINES | SANOFI-SYNTHELABO (FR) | 2001-04-12 | — | — | WO | claimed |
| WO-1998043635-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF A N-PIPERIDINO- 3-PYRAZOLECARBOXAMIDE DERIVATIVE, ITS SALTS AND THEIR SOLVATES | SANOFI-SYNTHELABO (FR) | 1998-10-08 | — | — | WO | claimed |
| EP-0656354-B1 | Substituted N-piperidino 3-pyrazolecarboxamide | SANOFI SA (FR) | 1997-06-04 | — | — | EP | claimed |
| US-5624941-A | Pyrazole derivatives, method of preparing them and pharmaceutical compositions in which they are present | SANOFI (FR) | 1997-04-29 | — | — | US | claimed |
| EP-0656354-A1 | Substituted N-piperidino 3-pyrazolecarboxamide | SANOFI (FR) | 1995-06-07 | — | — | EP | claimed |